YES.On Friday, Goldman Sachs analyst Jami Rubin upgraded the stock to neutral from sell, noting that the success of several recent drug launches bodes well for simeprevir and ibrutinib, two products currently awaiting FDA approval. Simeprevir is a hepatitis C drug that J&J eventually hopes to combine with a drug it just acquired from GlaxoSmithKline (GSK) to form an all-oral therapy for hepatitis C. Ibrutinib is a treatment for blood cancer developed by Pharmacyclics (PCYC), which won a "breakthrough therapy" designation from the FDA to speed up its review process.
Despite some good news about Gilead Sciences ' (GILD) rival idelalisib drug last week, Goldman Sachs analyst Navdeep Singh set his peak annual sales estimate for ibrutinib at $7.5 billion.
OK...so GILD's HepC is predicted avg. "PEAK SALES" of $7.4B :) The big buzz now surrounds Gilead's hepatitis C drug Sofosbuvir. Already touted as a megablockbuster, an FDA decision on sofosbuvir is expected in December, around the time competitor Johnson & Johnson hears about its simeprevir. The average analyst estimate for peak sales of sofosbuvir is $7.4 billion.
And Idelalisib..is just icing on the cake..:)))) GLTA big market for both!! :))